| Similar Articles |
 |
The Motley Fool June 10, 2004 Alyce Lomax |
Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition.  |
The Motley Fool June 2, 2004 Alyce Lomax |
Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine?  |
The Motley Fool March 9, 2004 Alyce Lomax |
February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers.  |
The Motley Fool July 6, 2004 Alyce Lomax |
Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them.  |
The Motley Fool March 22, 2004 Alyce Lomax |
Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good.  |
The Motley Fool July 6, 2007 Lawrence Rothman |
Walgreen Does It Again The company continues to impress, posting positive same-store sales results month after month. At a P/E of 21, this stock isn't especially rich, given the solid performance that the company delivers.  |
The Motley Fool June 11, 2007 Mike Cianciolo |
Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note.  |
The Motley Fool January 5, 2004 Jeff Hwang |
Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales.  |
The Motley Fool April 9, 2007 Mike Cianciolo |
CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.  |
The Motley Fool March 28, 2005 Alyce Lomax |
A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen?  |
The Motley Fool July 6, 2004 Steven Mallas |
Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%.  |
The Motley Fool September 14, 2006 Ryan Fuhrmann |
Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector.  |
The Motley Fool January 3, 2005 Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.  |
The Motley Fool December 11, 2006 Matthew Crews |
Rite Aid: Comps Mean Competition The pharmacy chain reported positive same-store results for November. Investors, take note.  |
The Motley Fool October 4, 2005 Seth Jayson |
Same Old Same-Store Story Reports from Walgreen and Rite Aid confirm the obvious. Investors will nearly always do better buying the best company in any given space.  |
The Motley Fool September 22, 2006 Ryan Fuhrmann |
More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note.  |
The Motley Fool January 5, 2007 Matthew Crews |
Rite Aid's Baby Steps If Rite Aid does manage 5% operating margins, this pharmacy chain's shares will get the love they deserve.  |
The Motley Fool February 4, 2005 Steven Mallas |
Walgreen's Wonderful Comps This drugstore chain doesn't need any medical attention. January comps prove it.  |
The Motley Fool May 5, 2004 Mike Cianciolo |
CVS Prescribes Growth The soon-to-be leader of the drugstore market had a spectacular first quarter as a result of improved sales and margins, and CVS doesn't appear to be showing any signs of slowing down either, as the company continues to expand its business in both traditional and creative ways.  |
The Motley Fool January 7, 2010 Gerard Torres |
Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition.  |
The Motley Fool February 12, 2004 Dave Marino-Nachison |
CVS Bags Big 2003 A strong year for the drugstore giant has spilled into January.  |
The Motley Fool July 6, 2007 Mike Cianciolo |
Walgreen: The New Deal Maker Walgreen announces its latest acquisition as it tries to keep pace with the competition. Investors, take note.  |
The Motley Fool July 29, 2011 Shubh Datta |
A Drug Retailer for Your Portfolio With a strong balance sheet, Walgreen looks like a good buy.  |
The Motley Fool January 4, 2008 Timothy M. Otte |
Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December.  |
The Motley Fool January 8, 2007 Matthew Crews |
CVS' Tightrope Walk The drugstore chain's aggressive growth strategy continues to pay off -- for now. Investors, take note.  |
The Motley Fool January 13, 2004 Alyce Lomax |
CVS Fever Drug stores benefit from the flu bug, but for how much longer?  |
The Motley Fool January 4, 2005 Seth Jayson |
Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship.  |
The Motley Fool October 8, 2011 Shubh Datta |
Impasse Hurts Walgreen's Quarter Walgreen posted a staggering 69% earnings jump but still saw its shares slide.  |
The Motley Fool June 29, 2007 Ryan Fuhrmann |
Rite Aid's Recent Remedy Will increased market clout lead the drugstore operator to new highs? Investors, take note.  |
The Motley Fool May 9, 2005 Timothy M. Otte |
Flu Means All's Well for CVS Strong comp sales and benefits from the Eckerd acquisition drive CVS to a solid first quarter. Investors, take note.  |
The Motley Fool April 4, 2007 Timothy M. Otte |
Walgreen's Comp Machine The drugstore operator steams through March with 8% comparable sales growth. The stock trades at a P/E of 24 times trailing-12-month earnings, about one-third higher than the average of all S&P 500 companies.  |
The Motley Fool September 27, 2004 Phil Wohl |
Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27.  |
The Motley Fool March 23, 2011 Andrew Bond |
What More Can You Ask of Walgreen? A sell-off in shares of Walgreen provides a buying opportunity for investors who want in on a best-of-breed company at a discount.  |
The Motley Fool January 3, 2012 Shubh Datta |
Bright Spots for Rite Aid Better same-store sales help Rite Aid trim losses.  |
The Motley Fool August 15, 2005 Bobby Shethia |
Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors.  |
The Motley Fool February 2, 2005 Alyce Lomax |
CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny.  |
The Motley Fool September 26, 2007 Ryan Fuhrmann |
Foolish Forecast: Does Rite Aid Have the Right Rx? The retail pharmacy is set to release it second-quarter financial results. Investors, here is what you can expect to see.  |
The Motley Fool September 26, 2006 Ryan Fuhrmann |
Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers?  |
The Motley Fool July 6, 2007 Timothy M. Otte |
Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's...  |
The Motley Fool August 1, 2007 Ryan Fuhrmann |
Foolish Forecast: CVS Caremark Gets Ready to Rumble CVS Caremark will announce its first combined quarterly results tomorrow. Competitors will be watching to see if the merger of drugstore chain and pharmacy benefit manager is a healthy one.  |
The Motley Fool August 3, 2007 Ryan Fuhrmann |
CVS Caremark Is No Sicko Pharmacy powerhouse CVS Caremark is looking to blaze a new health-care trail with the recent merger of their drugstore and pharmacy benefit management operations.  |
The Motley Fool June 28, 2005 Mike Cianciolo |
Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever.  |
The Motley Fool November 11, 2011 Dan Caplinger |
Has Walgreen Become the Perfect Stock? Given that drug retail is a low-margin business, it's improbable that Walgreen will ever reach true perfection. But with some help, improving growth numbers is a goal that could be within reach.  |
The Motley Fool April 13, 2007 Ryan Fuhrmann |
Rite Aid's Right-Size Ambitions If the retail pharmacy chain can improve its net margins, reduce debt, and smoothly integrate its latest acquisition, the stock's upside would be substantial.  |
The Motley Fool June 6, 2006 Ryan Fuhrmann |
Harry's Happy With Walgreen Walgreen acquires the Happy Harry's pharmacy chain. Investors, take note.  |
The Motley Fool June 26, 2007 Ryan Fuhrmann |
Walgreen Sells Convenience Walgreen continues to grow market share, with little sign of slowing down.  |
The Motley Fool March 9, 2005 Steven Mallas |
CVS Comps Feast on Flu CVS enjoys a nice jump in same-store sales for the month of February -- thanks, in part, to colds and the flu.  |
The Motley Fool December 21, 2007 Timothy M. Otte |
Walgreen Shapes Up for 2008 The drugstore chain reports lower expenses in the first quarter while pumping up sales.  |
The Motley Fool October 5, 2007 Timothy M. Otte |
CVS: Consistently Very Solid The drugstore giant scores a consistent sales increase in September, as it begins to capitalize on synergies from its CareMark acquisition.  |
The Motley Fool June 25, 2004 Steven Mallas |
Rite Aid in the Shadows The first quarter for Rite Aid, the pharmaceutical retailer, shows a profit, but is it time to add this stock to your portfolio?  |